Huntington's drug safety study halted early

NCT ID NCT05655520

Terminated Disease control Sponsor: Supernus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if the drug SAGE-718 is safe for people with Huntington's disease when taken over a long period. It was an open-label study, meaning everyone knew they were getting the drug. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Huntington disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUNTINGTON'S DISEASE

Contacts and locations

Locations

Sage Investigational Site

Birmingham, Alabama, 35233, United States
Sage Investigational Site

Little Rock, Arkansas, 72205, United States
Sage Investigational Site

La Jolla, California, 92037, United States
Sage Investigational Site

Los Alamitos, California, 90720, United States
Sage Investigational Site

Los Angeles, California, 90095, United States
Sage Investigational Site

Sacramento, California, 95817, United States
Sage Investigational Site

Englewood, Colorado, 80113, United States
Sage Investigational Site

Washington D.C., District of Columbia, 20007, United States
Sage Investigational Site

Boca Raton, Florida, 33431, United States
Sage Investigational Site

Tampa, Florida, 33612, United States
Sage Investigational Site

Chicago, Illinois, 60611, United States
Sage Investigational Site

Chicago, Illinois, 60612, United States
Sage Investigational Site

Indianapolis, Indiana, 46202, United States
Sage Investigational Site

Iowa City, Iowa, 52242, United States
Sage Investigational Site

Kansas City, Kansas, 66103, United States
Sage Investigational Site

Baltimore, Maryland, 21287, United States
Sage Investigational Site

Boston, Massachusetts, 02215, United States
Sage Investigational Site

New York, New York, 10032, United States
Sage Investigational Site

Williamsville, New York, 14221, United States
Sage Investigational Site

Chapel Hill, North Carolina, 27599, United States
Sage Investigational Site

Durham, North Carolina, 27705, United States
Sage Investigational Site

Cincinnati, Ohio, 45219, United States
Sage Investigational Site

Toledo, Ohio, 43614, United States
Sage Investigational Site

Philadelphia, Pennsylvania, 19107, United States
Sage Investigational Site

Charleston, South Carolina, 29425, United States
Sage Investigational Site

Memphis, Tennessee, 38157, United States
Sage Investigational Site

Houston, Texas, 77030, United States
Sage Investigational Site

Richmond, Virginia, 23298, United States
Sage Investigational Site

Spokane, Washington, 99202, United States
Sage Investigational Site

Westmead, New South Wales, 2145, Australia
Sage Investigational Site

Caulfield South, Victoria, 3162, Australia
Sage Investigational Site

Nedlands, Western Australia, 6009, Australia
Sage Investigational Site

Halifax, Nova Scotia, B3S1N2, Canada
Sage Investigational Site

Toronto, Ontario, M2K 1E1, Canada
Sage Investigational Site

Montreal, Quebec, H2X1R9, Canada
Sage Investigational Site

Plymouth, Derriford, PL6 8BT, United Kingdom
Sage Investigational Site

Southampton, England, SO16 6YD, United Kingdom
Sage Investigational Site

Tooting, London, SW17 0QT, United Kingdom
Sage Investigational Site

Aberdeen, Scotland, AB25 2ZA, United Kingdom
Sage Investigational Site

Newcastle, Upon Tyne, NE6 4QD, United Kingdom
Sage Investigational Site

Cardiff, Wales, CF144XW, United Kingdom
Sage Investigational Site

Birmingham, West Midlands, B15 2FG, United Kingdom
Sage Investigational Site

Leeds, West Yorkshire, LS7 4SA, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.